Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2010

Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, et al. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A. 2010;107(24):11002-7.

Dentice M, Marsili A, Ambrosio R, Guardiola O, Sibilio A, Paik J-, et al. The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. J Clin Invest. 2010;120(11):4021-30.

Krieger MH, Di Lorenzo A, Teutsch C, Kauser K, Sessa WC. Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice. Lab Invest. 2010;90(11):1573-81.

Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010;177(1):415-23.

Magro CM, A Crowson N, Mihm MC, Gupta K, Walker MJ, Solomon G. The dermal-based borderline melanocytic tumor: a categorical approach. J Am Acad Dermatol. 2010;62(3):469-79.

Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038-46.

Yao H, Hwang J-, Moscat J, Diaz-Meco MT, Leitges M, Kishore N, et al. Protein kinase C zeta mediates cigarette smoke/aldehyde- and lipopolysaccharide-induced lung inflammation and histone modifications. J Biol Chem. 2010;285(8):5405-16.

Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2088-96.

Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010;5(6):e11208.

Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, et al. Tissue-based molecular markers for bladder cancer. Minerva Urol Nefrol. 2010;62(3):241-58.